Karen Anderson joined Alnylam in 2014 from Biogen Idec where she served as Vice President, Human Resources for Research & Design (R&D) and Corporate Development.
Prior to Biogen Idec, Karen was the Vice President of Human Resources, Commercial for Pfizer Inc., covering both Developed Markets and Emerging Markets. Earlier in her 10-year tenure with Pfizer, Karen supported Worldwide R&D. Before joining Pfizer, she spent 6 years at Baxter in multiple roles, including Global Human Resources Director. Her career as a human resources leader in the biopharma industry began in 1995, when she joined Bayer as Director of Compensation from her role as an Associate Consultant with the Hay Group.
Karen received an MA degree in Organizational Psychology and Development from Bowling Green State University in Ohio. She earned her BA with honors in both Psychology and Labor Relations from York University in Toronto, Canada, and serves on the Board of Directors for Advancing Women in the Enterprise of Science & Technology.
Dr. Emmanuel Dulac joined Alnylam in August 2016, and is responsible for establishing the Alnylam global commercial footprint. He leads the development of the global commercial organization, building global commercial capabilities, including support of patients post product launch, and building the US commercial operations.
Emmanuel brings more than 20 years of international experience to Alnylam in the biotech and pharmaceutical industry. He joins the company from Shire where he was Senior Vice President, Head of the Rare Disease Business Unit. In this function, Emmanuel led the growth of a portfolio of 5 global brands worth $500 million and developed an innovative patient service hub. Prior to Shire, Emmanuel held various roles of increasing responsibility at Sanofi, Abbott, and Novartis in global, regional, and local functions.
Emmanuel graduated from the University of Paris XI with a Doctorate in Pharmacology (PharmD, PhD) and completed an MBA degree from the ESSEC School in Paris.
Barry Greene joined Alnylam in 2003 and has more than 25 years of experience in healthcare, pharmaceutical, and biotechnology industries.
Prior to Alnylam, Barry was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful approval and launch of VELCADE® (bortezomib) in mid-2003. Prior to joining Millennium in February 2001, Barry served as Executive Vice President and Chief Business Officer for Mediconsult.com. Preceding that, Barry’s past experiences include Vice President of Marketing and Customer Services for AstraZeneca, formerly AstraMerck; Vice President Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and Partner, Andersen Consulting, responsible for the pharmaceutical/biotechnology marketing and sales practice.
Barry received his BS degree in Industrial Engineering from University of Pittsburgh and served as Senior Scholar at Duke University, Fuqua School of Business. Barry also serves on the Boards of Acorda Therapeutics and Karyopharm Therapeutics.
Dr. Yvonne Greenstreet possesses 25 years of global experience in the pharmaceutical industry, where she has been in senior roles in research and development, strategy, and portfolio management. She has successfully led product development and commercialization teams in a wide range of therapy areas, bringing new medicines to patients.
Yvonne was previously Senior Vice President and Head of Medicines Development at Pfizer, and a member of the executive team for the specialty business, with accountability for a portfolio that included the immuno-inflammation, vaccine, specialty neuroscience, and rare disease areas. Prior to Pfizer, Yvonne held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President and Chief of Strategy for Research and Development, Senior Vice President for Medicines Development and Chief Medical Officer for Europe.
Yvonne received her medical degree (MBChB) from the University of Leeds, UK, and an MBA degree from INSEAD, France.
Dr. Pushkal Garg joined Alnylam in 2014 with 15 years of experience in clinical drug development. He oversees clinical research & operations, biometrics & data management, and medical writing groups.
Prior to joining Alnylam, Dr. Garg served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). He was the strategic leader of the Immunoscience franchise and successful developer of multiple clinical assets across the areas of rheumatology, gastroenterology, nephrology, and transplantation. While at BMS, he was instrumental to the late-stage development and approval of Nulojix® (belatacept) for kidney transplant recipients, and for supplementary biologics license applications (BLAs) for Orencia® (abatacept). Preceding this, Dr. Garg held various roles at Millenium Pharmaceuticals, overseeing the clinical development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders.
Dr. Garg received a Bachelor of Arts with high honors in Biochemistry from the University of California, Berkeley, and a medical degree from the University of California, San Francisco. He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women’s Hospital in Boston prior to joining the industry.
Laurie Bartlett Keating joined Alnylam in 2014 with more than 25 years of executive experience at high technology and biotechnology companies.
Prior to joining Alnylam, Laurie served as Senior Vice President, General Counsel and Secretary of Millennium: The Takeda Oncology Company for 9 years, responsible for setting the company’s global legal, intellectual property, and corporate quality strategies and priorities. Prior to Millennium, Laurie was co-founder and the first CEO of Hydra Biosciences, Inc. Before co-founding Hydra, she served as an executive at high-growth technology companies, including Iomega Corporation, and Sybase, Inc., a software company that grew from a few hundred to 6,000 employees during Laurie’s tenure on the management team. Based on her leadership at Sybase, Laurie was named one of the 45 most influential in-house lawyers in the United States under the age of 45. Upon graduating from law school, Laurie practiced law at McCutchen, Doyle, Brown and Enersen (now Bingham McCutchen) in San Francisco.
She has a Doctor of Jurisprudence degree from the University of California, Hastings College of the Law, and a BA in Economics from the University of California at Berkeley. Laurie is a member of the Board of Directors of MassBio, and the immediate past chair of the BIO General Counsels Committee.
Since 2002, Dr. John Maraganore has served as the CEO and a Director of Alnylam.
Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases. He was previously Vice President, Strategic Planning and M&A and, prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company.
Dr. Maraganore received his MS and PhD in biochemistry and molecular biology at the University of Chicago. He is a Director for bluebird bio, Inc., and is the Chairman of the Board for Agios Pharmaceuticals. Dr. Maraganore is a member of the Biotechnology Industry Organization (BIO) Board and the BIO Executive Committee, and serves as co-chair of the Regulatory Environment Committee.
Manmeet Soni joined Alnylam in June 2017. He provides strategic leadership over all financial management company-wide, including the global finance, investor relations, and communications teams.
Prior to joining Alnylam, Manmeet served as Chief Financial Officer and Treasurer of ARIAD Pharmaceuticals, Inc., where he played a central role in the strategic review, turnaround, and subsequent acquisition of ARIAD Pharmaceuticals, Inc. by Takeda Pharmaceuticals Company Limited. Before joining ARIAD Pharmaceuticals, Inc., Manmeet worked at Pharmacyclics, Inc., where he served most recently as Chief Financial Officer and Treasurer. He also played a vital role in the acquisition of Pharmacyclics, Inc. by Abbvie, Inc. for $21 billion. Previously, Manmeet worked at ZELTIQ Aesthetics Inc., and PricewaterhouseCoopers San Jose, in the Life Science and Venture Capital Group. Prior to that, he worked at PricewaterhouseCoopers India.
Manmeet is currently a board member and audit committee chair at Genoscience Pharma. He graduated from Hansraj College at Delhi University in India. He is a Certified Public Accountant, licensed in the state of California, and a Chartered Accountant from India.
Dr. Akshay Vaishnaw joined Alnylam in 2006, coming from Biogen, Inc. (now Biogen Idec Inc.), where he was most recently Senior Director, Translational Medicine.
In his 7 years at Biogen, Dr. Vaishnaw was involved in many aspects of clinical research and business development, and led the effort for the approval of AMEVIVE® (alefacept) for psoriasis.
Dr. Vaishnaw received his MD from the University of Wales College of Medicine, UK, and his PhD from the University of London, UK, in Molecular Immunology. He is a Fellow of the Royal College of Physicians, UK. Dr. Vaishnaw is a member of the Scientific Advisory Board of Scholar Rock, and a member of the Board of Directors for Visterra, Inc., and for Editas Medicine. In addition, he has published papers in leading scientific journals and authored several textbook chapters relating to autoimmune disease.
The Alnylam Board of Directors is composed of accomplished leaders from the healthcare industry who bring their experience in science, drug development, commercialization, and strategy to our efforts in developing RNAi (RNA interference) therapeutics.
Former Chief Executive Officer and Director of Cubist Pharmaceuticals and former Partner of Third Rock Ventures; Director of Celgene Corporation, Global Blood Therapeutics, Inc., and Revolution Medicines, Inc.; and Trustee of Gulf of Maine Research Institute and Tekla fund complex, focused on healthcare investing.
Director of the Center for Assessment Technology and Continuous Health (CATCH) and Physician‐in‐Chief Emeritus at Massachusetts General Hospital, and Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School; Director of Pfizer, Inc., and Seres Therapeutics, Inc.
Managing General Partner, Cardinal Partners; founder of Alnylam, Alkermes, Inc., and Cubist Pharmaceuticals, Inc., and Chairman of the Board of Directors of aTyr Pharma, Inc.
Former Chief Financial Officer of Millennium Pharmaceuticals and serves on the Board of Directors at Ironwood Pharmaceuticals, Inc., and Momenta Pharmaceuticals, Inc.
Chief Executive Officer of Alnylam and serves on the Board of Directors at bluebird bio, Inc., and Agios Pharmaceuticals.
Chief Executive Officer, President, and board member of Voyager Therapeutics, Inc.; Venture Partner at Third Rock Ventures; co-founder and board member of SAGE Therapeutics; trustee for the Foundation for the National Institute of Mental Health (NIMH); former President of the Lilly Research Laboratories of Eli Lilly and Company, and former Scientific Director of the NIH.
Former Chairman and Chief Executive Officer of Allergan; Lead Director of Avery Dennison Corporation; member of the Supervisory Board of Royal Philips in the Netherlands, and director of BioMarin Pharmaceuticals, Inc.
Ernest and Jean Hahn Professor of Molecular Biology and Chemistry at Scripps Research Institute; founder of Alnylam; member of the National Academy of Sciences, American Academy of Arts and Sciences, and the Institute of Medicine; co-founder of Cubist, Alkermes, and Repligen; and co-founder and director of aTyr Pharma, Inc.
Chief Executive Officer and board member of Arsia Therapeutics; co-founder, President, and Chief Executive Officer of Lyndra, Inc.; Venture Partner at Polaris Partners; former Executive Vice President and General Counsel of Pfizer Inc.; served as the Business Unit Lead for the Pfizer Consumer Healthcare business; senior lecturer at Harvard Business School and director of Blue Buffalo Pet Products, Inc.
Institute Professor, The Koch Institute for Integrative Cancer Research, MIT; founding director of McGovern Institute for Brain Research, MIT; Nobel Laureate; founder of Alnylam; co-founder and former director of Biogen, Inc.; member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences.
Third Rock Ventures partner; Chairman of Decibel Therapeutics, Inc.; former Chief Operating Officer and Chief Financial Officer of Millennium Pharmaceuticals, Inc.; director of Ember Therapeutics and SAGE Therapeutics, Inc.